5-year follow-up results of cll14: obinutuzumab venetoclax vs obinutuzumab chlorambucil in cll
Published 2 years ago • 728 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
5:59
6-year results of cll14: venetoclax-obinutuzumab for previously untreated cll
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
5:54
cll14: venetoclax plus obinutuzumab for cll
-
1:13
5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
-
2:43
four-year follow-up from a phase ii study of obinutuzumab, ibrutinib, and venetoclax in cll
-
10:24
fixed-duration therapy with venetoclax-obinutuzumab in frontline cll
-
18:56
the announcement of chad and april
-
5:00
venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline cll: updates from gaia/cll13
-
1:32
cll14: feasibility of fixed-duration frontline therapy in cll
-
1:24
5-year update of elevate cll tn
-
1:59
cll resonate-2: five-year follow-up
-
6:34
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
3:58
five-year follow up of the uk cll forum ibrutinib data
-
1:56
the future of fixed-duration therapy in cll
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
2:02
important prognostic factors to evaluate in cll patients in the era of small molecules
-
1:40
elevate-tn: 4-year follow-up shows pfs benefit of a or a o over o clb for cll
-
1:52
resonate: five-year follow-up of ibrutinib for cll
-
2:56
undetectable mrd after obinutuzumab plus venetoclax in cll
-
3:46
long-term follow-up of venetoclax in cll
-
6:25
murano: five-year follow-up on venetoclax plus rituximab for cll